GENE ONLINE|News &
Opinion
Blog

.

Зеркало официального сайта всегда доступно для входа на Мостбет, даже при ограничениях. Скачать Mostbet – это шаг к удобству и азартным развлечениям.

Если вы ищете место для увлекательных ставок, обратите внимание на Joycasino, где лучшие предложения для игроков ждут вас.
2022-01-07|

Novartis Teams Up with Alnylam to Explore Targeted Liver Therapies

by Arvind C. Shekhar
Share To

Novartis announced a collaboration with Alnylam Pharmaceuticals to develop a treatment that can restore liver function and offer an alternative to transplants in patients with end-stage liver disease. The collaboration will leverage Alnylam’s proven and proprietary siRNA technology to inhibit an unspecified drug target discovered at the Novartis Institutes for biomedical Research. 

 

Implications of End-stage Liver Disease (ESLD) 

 

End-stage liver disease (ESLD) is a progressive illness, most often resulting from cirrhosis, that is characterized by the destruction of healthy liver tissue and the loss of critical liver function.  

The most common causes of ESLD are alcoholic liver disease, hepatitis C and hepatic steatosis (fatty liver) resulting from obesity.  ESLD accounts for over one million deaths globally each year apart from having a profound impact on patients’ quality of life. 

Currently, liver transplantation is the only treatment for ESLD and a significant need exists for medicinal alternatives that regenerate liver tissue and restore the essential metabolic and synthetic processes that are managed by the liver. Transplants are not only expensive, invasive procedures, but also not feasible due to a limited supply of organs available for patients in need.

 

The Collaboration and Its Objectives

 

“There remains an enormous unmet need for new types of medicines to address end-stage liver disease,” said Jay Bradner, President of the Novartis Institutes for biomedical Research. 

“Building on a legacy of leadership in regenerative medicine, we have devised a restorative strategy that could potentially deliver a transformative benefit to patients with liver failure. We’re delighted now to work alongside Alnylam in this new collaboration, as the Alnylam siRNA platform is optimally suited to translate this concept to clinical investigation.”

During the exclusive three-year research collaboration, Alnylam will develop and test potential siRNAs using target-specific assays developed by Novartis. Once a lead candidate is identified, further development and clinical research will be conducted by Novartis.

“We are so pleased to collaborate with Novartis,” said Kevin Fitzgerald, Ph.D., Chief Scientific Officer at Alnylam. “We believe collaborations like this serve as an excellent example of how Alnylam’s leadership in RNAi can fuel new frontiers of medicine with highly innovative targets coming from some of the most admired pharmaceutical companies.”

©www.geneonline.com All rights reserved. Collaborate with us: [email protected]
Related Post
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
Pharma’s Growing (R)evolution: Sustainability and Innovations Shaping the Industry
2025-01-07
Biotech Industry Trends in 2024: A Look at the Billions in Oncology Deals
2024-09-18
LATEST
Beyond Pouch Packaging: Hanmi Pharmaceutical Introduces a New Automated Vial Dispensing Solution in Canada and the United States
2025-02-13
NASA Says There’s a 1 in 43 Chance an Asteroid 2024 YR4 Could Hit Earth in 2032—Should We Worry?
2025-02-13
Sodium Channel Targeting: What the Latest FDA Non-Opioid Approval Reveals About the Next Big Thing in Pain Relief
2025-02-12
Novartis Reclaims Abelacimab in $925M Deal to Boost Cardiovascular Portfolio
2025-02-12
GLP-1 Weight Loss Drugs Might Cause Blindness
2025-02-11
South Korea’s Olix Strikes $660M Deal with Eli Lilly for Phase 1 MASH candidate
2025-02-11
22 USA States Sue Trump Administration for Slashing Critical Medical Research Funding
2025-02-11
EVENT
2025-02-19
Healthcare Conference Taipei 2025
Taipei, Taiwan
2025-03-04
MIXiii Health-Tech.IL
Jerusalem, Israel
2025-03-05
Medical Japan
Osaka, Japan
2025-03-17
BIO-Europe Spring 2025
Milan, Italy
2025-04-21
World Vaccine Congress Washington 2025
Washington, U.S.A
Scroll to Top